- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05667883
Prognostic Model of GC/CTX in the Treatment of MN
Development and Validation of a Prognostic Model for Idiopathic Membranous Nephropathy Treated With Glucocorticoids Plus Cytoxan
The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + cytoxan. The main questions it aims to answer are:
- to explore the factors that can predict the prognosis difference in patients with IMN under the treatment of glucocorticoid + cytoxan
- to establish a clinical prediction model and verify it to provide a reference for the early Participants will receive standard glucocorticoid + cytoxan treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. Blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy.
Researchers will compare [remission group and non-remission group] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 18-75 years, the patient was diagnosed as idiopathic membranous nephropathy or anti phospholipase A2 receptor (PLA2R) antibody positive by renal puncture biopsy, and the clinical data were complete;
- According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in 2020, it conforms to the medium and high risks in the risk level of progression of renal function loss.
- In general, they are in good condition, have a good understanding of their own conditions and physical conditions, have self-awareness, and can communicate well with others;
- Volunteer to participate in the study, understand the significance of this experiment and the indicators to be measured, and sign the informed consent form.
Exclusion Criteria:
- There are factors causing secondary membranous nephropathy, such as immune diseases (systemic lupus erythematosus), tumors/infections (viral hepatitis), drugs or toxins;
- At the same time, immunoglobulin A nephropathy (IgAN), interstitial nephritis, acute nephritis and other renal pathological types were combined;
- The medication was not standardized during the treatment process, accompanied by serious infection, acute renal injury and other complications, and serious cardiovascular, cerebrovascular, digestive and blood system diseases;
- During follow-up, the patient cannot actively cooperate or accurately understand and express.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Remission
|
The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d;
Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
|
Non-remission
|
The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d;
Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission
Time Frame: 6 months
|
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Urologic Diseases
- Nephritis
- Glomerulonephritis
- Kidney Diseases
- Glomerulonephritis, Membranous
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Glucocorticoids
Other Study ID Numbers
- IMN-GC/CTX
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Membranous Nephropathy
-
Beijing Friendship HospitalRecruitingIdiopathic Membranous NephropathyChina
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Peking Union Medical College HospitalBeijing Tongren Hospital; Shanghai Fosun Pharmaceutical Industrial Development... and other collaboratorsRecruitingIdiopathic Membranous NephropathyChina
-
wanglinCompletedIdiopathic Membranous NephropathyChina
-
Guangdong Provincial People's HospitalTerminatedIdiopathic Membranous NephropathyChina
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownIdiopathic Membranous NephropathyChina
-
SynAct Pharma ApsRecruitingNephrotic Syndrome Due to Idiopathic Membranous Nephropathy | Severe Proteinuria Due to Idiopathic Membranous NephropathyDenmark
-
Qianfoshan HospitalNot yet recruitingIdiopathic Membranous Nephropathy
-
Assistance Publique - Hôpitaux de ParisCompletedIdiopathic Membranous NephropathyFrance
Clinical Trials on glucocorticoid + cytoxan
-
Emory UniversityEmmaus Medical, Inc.Completed
-
Baylor College of MedicineCompleted
-
Nottingham Trent UniversitySuspended
-
Phramongkutklao College of Medicine and HospitalCompletedSystemic Lupus Erythematosus, SLEThailand
-
Dana-Farber Cancer InstituteAdenoid Cystic Carcinoma Research Foundation; The V FoundationCompletedAdenoid Cystic CarcinomaUnited States
-
First Affiliated Hospital of Suzhou Medical CollegeCompletedImmune Thrombocytopenic PurpuraChina
-
Wenhu LiuTerminatedIdiopathic Membranous NephropathyChina
-
Washington University School of MedicineRecruitingPulmonary Hypertension | Bronchopulmonary Dysplasia | Pulmonary Hypertension Due to Lung Diseases and HypoxiaUnited States
-
Diakonhjemmet HospitalVestre Viken Hospital Trust; Hormone Laboratory, Aker University Hospital,...Not yet recruitingOsteoporosis | Inflammatory Rheumatism | Osteoporosis, Steroid Induced
-
University Hospital OlomoucPalacky UniversityRecruitingUrinary Incontinence | Prostate Cancer | Radical Prostatectomy | Pelvic Floor Muscle Training | Beta-AlanineCzechia